全文获取类型
收费全文 | 2075811篇 |
免费 | 142609篇 |
国内免费 | 4150篇 |
专业分类
耳鼻咽喉 | 26903篇 |
儿科学 | 67729篇 |
妇产科学 | 55655篇 |
基础医学 | 305884篇 |
口腔科学 | 58211篇 |
临床医学 | 186834篇 |
内科学 | 400860篇 |
皮肤病学 | 47275篇 |
神经病学 | 155927篇 |
特种医学 | 78255篇 |
外国民族医学 | 293篇 |
外科学 | 313422篇 |
综合类 | 44520篇 |
现状与发展 | 5篇 |
一般理论 | 620篇 |
预防医学 | 153357篇 |
眼科学 | 49212篇 |
药学 | 152366篇 |
8篇 | |
中国医学 | 5133篇 |
肿瘤学 | 120101篇 |
出版年
2019年 | 16115篇 |
2018年 | 23728篇 |
2017年 | 17917篇 |
2016年 | 19849篇 |
2015年 | 22484篇 |
2014年 | 31052篇 |
2013年 | 45206篇 |
2012年 | 63479篇 |
2011年 | 67292篇 |
2010年 | 39636篇 |
2009年 | 36913篇 |
2008年 | 62439篇 |
2007年 | 66980篇 |
2006年 | 67014篇 |
2005年 | 64009篇 |
2004年 | 61881篇 |
2003年 | 59048篇 |
2002年 | 56912篇 |
2001年 | 106217篇 |
2000年 | 108382篇 |
1999年 | 89420篇 |
1998年 | 23370篇 |
1997年 | 20402篇 |
1996年 | 20426篇 |
1995年 | 19614篇 |
1994年 | 17900篇 |
1993年 | 16631篇 |
1992年 | 67264篇 |
1991年 | 66154篇 |
1990年 | 64142篇 |
1989年 | 61695篇 |
1988年 | 56367篇 |
1987年 | 55128篇 |
1986年 | 51793篇 |
1985年 | 49240篇 |
1984年 | 36217篇 |
1983年 | 30771篇 |
1982年 | 17037篇 |
1979年 | 32358篇 |
1978年 | 22494篇 |
1977年 | 18841篇 |
1976年 | 18061篇 |
1975年 | 19695篇 |
1974年 | 23411篇 |
1973年 | 22560篇 |
1972年 | 20878篇 |
1971年 | 19479篇 |
1970年 | 18161篇 |
1969年 | 16930篇 |
1968年 | 15889篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
41.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
42.
43.
Provocation of Atrial Fibrillation Triggers During Ablation: Does the Use of General Anesthesia Affect Inducibility? 下载免费PDF全文
44.
C. Dessinioti C.C. Zouboulis V. Bettoli D. Rigopoulos 《Journal of the European Academy of Dermatology and Venereology》2020,34(10):2229-2240
Guidelines and consensus on the management of patients with acne aim to give evidence-based, expert-group recommendations. This review compares current guidelines and consensus articles to provide a compilation of recommendations on the treatment of acne with oral isotretinoin. Ten common, relevant, clinical questions are addressed, based on published recommendations, including the indications of isotretinoin, the proposed daily dose, the cumulative isotretinoin dose and the laboratory monitoring needed. Recommendations on special considerations are also addressed, including the timing of procedures and the question of an association of depression or inflammatory bowel disease with isotretinoin. A major limitation is the use of different classification systems for acne across guidelines. The recommended daily dose ranges from 0.3 to 0.5 mg/kg in the European guidelines to up to 1 mg/kg in the US guidelines. A specific duration of treatment of at least 6 months is only recommended in the European guidelines. All guidelines report the need of strict pregnancy prevention measures. The European, French and US guidelines recommend to monitor for symptoms of depression. Important clinical questions that are inconsistently addressed in guidelines include the age indication, the recommendation for a cumulative dose, the timing of procedures, the association of isotretinoin with IBD, the recommendation for preventing acne flares and for appropriate laboratory monitoring. These topics should be clearly included in the recommendations of guidelines as they are often raised in everyday clinical practice. 相似文献
45.
46.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
47.
48.
49.
50.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文